Silence Therapeutics plc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SLN$19.75+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders' Equity
SILENCE THERAPEUTICSPLC
Consolidated statements of changes in SHAREHOLDERS' equity
| Ordinary Shares | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Note · Shares · Cost · Additional paid-in capital · Accumulated other comprehensive income · Accumulateddeficit · Total shareholders'equity | |||||||||
| At January 1, 2022 | 89,784,720 | $7,065 | $346,699 | $(11,428) | $(329,962) | $12,374 | |||
| Net loss | - | - | - | - | (50,334) | (50,334) | |||
| Foreign currency translation adjustments (net of tax) | - | - | - | $(86) | - | (86) | |||
| Recognition of share-based payments | - | - | 12,686 | - | - | 12,686 | |||
| Options exercised in the year | 173,752 | - | (238) | - | 238 | - | |||
| Proceeds from shares issued | 17,850,000 | 1,086 | 51,495 | - | - | 52,581 | |||
| At December 31, 2022 | 107,808,472 | $8,151 | $410,642 | (11,514) | $(380,058) | $27,221 | |||
| Net loss | - | - | - | - | (54,228) | (54,228) | |||
| Foreign currency translation adjustments (net of tax) | - | - | - | 789 | - | 789 | |||
| Recognition of share-based payments | 19 | - | - | 16,274 | - | - | 16,274 | ||
| Options exercised in the year | 18/19 | 807,927 | - | (2,392) | - | 2,392 | - | ||
| Proceeds from shares issued | 10,230,567 | 696 | 31,241 | - | - | 31,937 | |||
| At December 31, 2023 | 118,846,966 | $8,847 | 455,765 | $(10,725) | $(431,894) | $21,993 | |||
| Net loss | - | - | - | (45,309) | (45,309) | ||||
| Foreign currency translation adjustments (net of tax) | - | - | - | (1,055) | - | (1,055) | |||
| Recognition of share-based payments | 19 | - | - | 16,307 | - | - | 16,307 | ||
| Options exercised in the year | 18/19 | 1,408,443 | - | (3,158) | - | 3,158 | - | ||
| Proceeds from shares issued | 21,418,665 | 1,441 | 140,646 | - | - | 142,087 | |||
| At December 31, 2024 | 141,674,074 | $10,288 | $609,560 | $(11,780) | $(474,045) | $134,023 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.